DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20213084

Emerging role of C-peptide as an early biomarker of metabolic syndrome

Rana Usmani, Tariq Masood, Kanika Kakkar, Gunjan Mishra, Adarsh Uniyal, Udit Nasa, Rajeev Singh Kushwaha

Abstract


Background: Metabolic syndrome is a health issue of rising concern as it has a correlation with the occurrence of cardiovascular events. Early identification of this syndrome by evaluating levels of biomarkers such as C peptide can help medical professionals prevent the occurrence of life-threatening cardiovascular diseases.

Methods: This cross-sectional study was carried out in 89 subjects who were diagnosed to have metabolic syndrome. General Physical examination was done and fasting C peptide and insulin levels were quantified, followed by statistical analysis and their correlation. The prevalence of defining parameters of Metabolic Syndrome as per IDF 2005 was studied.

Results: Out of 89 (100%) subjects, 80 (89.8%) subjects (Mean±SD=6.14±3.47) had C- peptide level >1.89 ng/ml which was statistically highly significant (p<0.001). Also, out of 89 (100%) subjects, 67 (24.71%) subjects had insulin level <25 mIU/L which was statistically significant (p<0.001).

Conclusions: It was thereby concluded that serum C peptide levels were raised in patients of Metabolic syndrome and it is superior to serum Insulin levels as an early biomarker of the same.


Keywords


Metabolic syndrome, Microvascular, Biomarker, Proinsulin

Full Text:

PDF

References


Shrestha S, Das BKL, Baral N, Chandra L. Association of metabolic syndrome and its components with thyroid dysfunctions in females. Int J Diab Dev Ctries. 2007;27:24-6.

International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/metabolic-syndrome. Accessed on 10 May, 2021.

Grundy SM. Obesity, metabolic syndrome and cardiovascular disease. J Clin Endoc Crinol Meta. 2004;89:2595-600.

IDF Consensus Worldwide Definition of the Metabolic Syndrome, available as PDF at https://www.idf.org/e-library/consensus-statements /60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html. Accessed on 10th May, 2021.

Alberti KG, Zimmet P, Shaw J. The metabolic syndrome–a new worldwide definition. Lancet. 2005;366:1059-62.

Deepa M, Farooq S, Deepa R, Manjula D, Mohan V. Prevalence and significance of generalised and central body obesity in an urban Asian Indian population in Chennai, India (CURES: 47). Eur J Clin Nutr Feb. 2009;63(2):259-67.

Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinology and Metabolism Clinics of North America. 2004;33(2):351-75.

Rubenstein A, Clark J, Melani F, and Steiner D. Secretion of proinsulin, C-peptide by pancreatic beta cells and its circulation in blood. Nature. 1969;224:697-9.

Tharkar S, Viswanathan V. Effect of obesity on cardiovascular risk factors in urban population in South India. Heart Asia. 2010;2:145-9.

Vasan SK, Thomas N, Christopher S, Geethanjali FS, Paul TV, Sanjeevi CB. Anthropometric measurements for the prediction of the metabolic syndrome: A cross-sectional study on adolescents and young adults from southern india. Heart Asia. 2011;3:2-7.

Ramchandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults - a population study using modified ATP-III criteria. Diabetes Res Clin Pract. 2003;60:199-204.

Hills CE, Brunskill NJ. Intracellular signalling by C-peptide. Experimental Diabetes Research. 2008;63:51-5.

Kim S T, Kim BJ, Lim DM, Song IG, Jung JH, Lee KW et al. Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients.Diabetes Metab J. 2011;35:41-9.

Haban P, Simoncic R, Zidekova E, Ozdin L. Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome. Med Sci Monit. 2002;8(3):CR175-9.

Chen CH, Tsai ST, Chou P. Correlation of fasting serum C-peptide and insulin with markers of metabolic syndrome-X in a homogenous Chinese population with normal glucose tolerance. Int J Cardiol. 1999;28;68(2):179-86.

Beliakin SA, Serebrennikov VN, Shklovskiĭ BL, Patsenko MB. C-peptide level as an early diagnostic marker of metabolic syndrome and predictor of cardiovascular disease in patients with diabetes mellitus type 2. Voen Med Zh. 2014;335(10):46-9.

Henriksen JH, Tronier B, Bulow JB. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. Metabolism. 1987;36:463-8.

Zavaroni I, Deferrari G, Lugari R, Bonora E, Garibotto G, Dall’Aglio E et al. Renalmetabolism of C-peptide in man. J Clin Endo crinol Metab. 1987;65:494-8.

Covic AM, Schelling JR, Constantiner M, Iyengar SK, Sedor JR. Serum C-peptide concentrations poorly phenotype type 2 diabeticend-stage renal disease patients. Kidney Int. 2000;58:1742-50.